Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with a healthcare provider before starting or stopping any medication.

Known Side Effects

The available evidence provides limited specific safety data for semaglutide. One Danish community pharmacy survey examined treatment patterns and experienced effects among adult users taking semaglutide for weight management, but detailed side effect profiles from this study are not provided in the evidence.

Evidence limitation: The current evidence does not include comprehensive safety data from major clinical trials or systematic reviews that would typically inform a complete side effect profile.

Contraindications

No specific contraindications for semaglutide are detailed in the provided evidence.

Evidence limitation: Standard contraindication information is not available in the current evidence base.

Drug Interactions

The evidence includes one terminated Phase 1 clinical trial (NCT05671653) that was designed to evaluate potential interactions between semaglutide and several medications, including:

Birth control pills
Omeprazole
Midazolam

However, since this study was terminated, no interaction data is available from this research.

Evidence limitation: No conclusive drug interaction data is provided in the available evidence.

Special Populations

Fertility and Reproductive Health

One review article examines GLP-1 receptor agonists (the drug class that includes semaglutide) and fertility, but specific findings are not detailed in the available evidence.

Pregnancy and Contraception

The terminated drug interaction study mentioned above was investigating effects on birth control pills, suggesting potential concerns about contraceptive efficacy, but no results are available.

Evidence limitation: The current evidence does not provide adequate information about safety in pregnancy, breastfeeding, pediatric populations, or elderly patients.

Overall Safety Assessment

Significant evidence limitations: The provided evidence lacks comprehensive safety data that would typically be expected for a complete safety profile, including:

Detailed adverse event rates from clinical trials
Black box warnings or serious safety concerns
Monitoring requirements
Dose-dependent side effects
Long-term safety data

Healthcare providers should consult current prescribing information, FDA labeling, and additional clinical literature for comprehensive safety guidance when considering semaglutide therapy.

Semaglutide